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Unfortunately, the online published article has errors in footnote of Tables 1, 2 and 3. The correct tables are given in the following pages.Table 1Basic characteristics of MS cases and matched referent subjects at cohort entry, overall and stratified by type of MSCharacteristicMS cases\
*N* = 1,822 \[*n* (%)\]Referents\
*N* = 18,211 \[*n* (%)\]RRMS^a^\
*N* = 769 \[*n* (%)\]Referents\
*N* = 7,690 \[*n* (%)\]PPMS\
*N* = 125 \[*n* (%)\]Referents\
*N* = 1,250 \[*n* (%)\]Mean age (years) at cohort entry (index date; SD)42.08 (11.79)42.0 (11.72)40.01 (11.14)39.94 (11.15)49.98 (10.43)49.92 (10.39)Sex Males481 (26.40)4,801 (26.36)193 (25.10)1,930 (25.10)53 (42.40)530 (42.40) Females1,341 (73.60)13,410 (73.64)576 (74.90)5,760 (74.90)72 (57.60)720 (57.60)Smoking status Current\*^,†^569 (31.23)4,363 (23.96)226 (29.39)1,902 (24.73)40 (32.00)289 (23.12) Former239 (13.12)2,390 (13.12)101 (13.13)963 (12.52)23 (18.40)199 (15.92) Never777 (42.65)8,921 (48.99)349 (45.38)3,807 (49.51)50 (40.00)595 (47.60) Unknown237 (13.01)2,537 (13.93)93 (12.09)1,018 (13.24)12 (9.60)167 (13.36)BMI (kg/m^2^) \<18.546 (2.52)379 (2.08)17 (2.21)179 (2.33)2 (1.60)18 (1.44) 18.5--24.99706 (38.75)6,948 (38.15)301 (39.14)2,980 (38.75)46 (36.80)408 (32.64) 25.0--29.99426 (23.38)4,100 (22.51)187 (24.32)1,676 (21.79)39 (31.20)339 (27.12) ≥30248 (13.61)2,406 (13.21)112 (14.56)993 (12.91)12 (9.60)198 (15.84) Unknown396 (21.73)4,378 (24.04)152 (19.77)1,862 (24.21)26 (20.80)287 (22.96)Alcohol abuse^†^25 (1.37)370 (2.03)3 (0.39)133 (1.73)5 (4.0)50 (4.0)Mean length of recorded medical history (years; SD) Before index date7.86 (4.44)7.97 (4.43)7.93 (4.50)8.03 (4.49)8.83 (4.51)9.02 (4.52) Follow-up after index date^†^7.85 (4.50)7.95 (4.49)8.95 (4.33)8.18 (4.40)8.15 (4.32)8.15 (4.08)Type of MS was determined from original clinical records for 894 patients*BMI* body mass index, *MS* multiple sclerosis, *PPMS* primary progressive MS, *RRMS* relapsing-remitting MS, *SD* standard deviation\* *p* \< 0.05 for comparison between patients with MS and matched referent subjects (for all MS patients)^†^ *p* \< 0.05 for comparison between patients with RRMS and matched referent subjects^a^Includes 64 patients with secondary progressive MSTable 2Comorbidities of MS cases and matched referent subjects at cohort entry, overall and stratified by type of MSCharacteristicMS cases\
*N* = 1,822 \[*n* (%)\]Referents\
*N* = 18,211 \[*n* (%)\]RRMS^a^ cases\
*N* = 769 \[*n* (%)\]Referents\
*N* = 7,690 \[*n* (%)\]PPMS cases\
*N* = 125 \[*n* (%)\]Referents\
*N* = 1,250 \[*n* (%)\]Chronic comorbidities^b^ COPD and asthma302 (16.58)2,890 (15.87)117 (15.21)1,245 (16.19)18 (14.40)197 (15.76) Depression\*^,†,§^508 (27.88)3,677 (20.19)188 (24.45)1,529 (19.88)45 (36.00)238 (19.04) Diabetes35 (1.92)390 (2.14)13 (1.69)141 (1.83)3 (2.40)44 (3.52) Hypertension137 (7.52)1,544 (8.48)47 (6.11)538 (7.00)13 (10.40)179 (14.32) Heart disease34 (1.87)439 (2.41)8 (1.04)119 (1.55)4 (3.20)64 (5.12) Cancer50 (2.74)558 (3.06)15 (1.95)223 (2.90)5 (4.00)50 (4.00)Acute comorbidities^c^ Acute respiratory infection^§^252 (13.83)2,673 (14.68)113 (14.69)1,143 (14.86)9 (7.20)171 (13.68) Pneumonia and influenza18 (0.99)169 (0.93)11 (1.43)70 (0.91)1 (0.80)14 (1.12) Urinary tract infection\*99 (5.43)683 (3.75)36 (4.68)284 (3.69)8 (6.40)41 (3.28) Skin infection164 (9.00)1,566 (8.60)68 (8.84)652 (8.48)5 (4.00)96 (7.68) Eye or Ear infection4 (0.22)33 (0.18)3 (0.39)15 (0.20)0 (--)0 (--) Other infection\*^,†^149 (8.18)1,256 (6.90)69 (8.97)533 (6.93)5 (4.00)73 (5.84) Dyspepsia35 (1.92)282 (1.55)11 (1.43)120 (1.56)2 (1.60)23 (1.84)Charlson Comorbidity Index at cohort entry Low (0)1,393 (76.45)14,192 (77.93)615 (79.97)6,048 (78.65)96 (76.80)931 (74.48) Medium (1--2)405 (22.23)3,822 (20.99)147 (19.12)1,574 (20.47)26 (20.80)296 (23.68) High (\>2)24 (1.32)197 (1.08)7 (0.91)68 (0.88)3 (2.40)23 (1.84)Type of MS was determined from original clinical records for 894 patients*COPD* chronic obstructive pulmonary disorder, *MS* multiple sclerosis, *PPMS* primary progressive MS, *RRMS* relapsing-remitting MS\* *p* \< 0.05 for comparison between patients with MS and matched referent subjects (for all MS patients)^†^ *p* \< 0.05 for comparison between patients with RRMS and matched referent subjects^§^ *p* \< 0.05 for comparison between patients with PPMS and matched referent subjects^a^Includes 64 patients with secondary progressive MS^b^Ever before, or at cohort entry^c^During the year before, or at index dateTable 3Comedications of MS cases and matched referent subjects at cohort entry, overall and stratified by type of MSCharacteristicAll MS cases\
*N* = 1,822 \[*n* (%)\]Referents\
*N* = 18,211 \[*n* (%)\]RRMS^a^ cases\
*N* = 769 \[*n* (%)\]Referents\
*N* = 7,690 \[*n* (%)\]PPMS cases\
*N* = 125 \[*n* (%)\]Referents\
*N* = 1,250 \[*n* (%)\]Comedications (at cohort entry \[index date\] or within the 6 months before) Systemic glucocorticoids\*^,†^180 (9.88)713 (3.92)69 (8.97)288 (3.75)8 (6.40)52 (4.16) Antidepressants\*^,†,§^380 (20.86)1,582 (8.69)132 (17.17)662 (8.61)28 (22.40)102 (8.16) Anticonvulsants\*^,†,§^122 (6.70)225 (1.24)40 (5.20)88 (1.14)11 (8.80)25 (2.00) Antidiabetics24 (1.32)283 (1.55)12 (1.56)112 (1.46)0 (--)30 (2.40) Opioids\*^,†,§^345 (18.94)1,585 (8.70)122 (15.86)621 (8.08)23 (18.40)133 (10.64) NSAIDs\*^,†^316 (17.34)1,806 (9.92)122 (15.86)710 (9.23)21 (16.80)152 (12.16) Statins\*61 (3.35)447 (2.45)20 (2.60)137 (1.78)4 (3.20)75 (6.00) Antibiotics\*^,†^403 (22.12)3,598 (19.76)179 (23.28)1,546 (20.10)16 (12.80)227 (18.16) Muscle relaxants\*^,†,§^173 (9.50)399 (2.19)50 (6.50)153 (1.99)20 (16.00)37 (2.96) Antipsychotics\*^,†^122 (6.70)387 (2.13)54 (7.02)160 (2.08)5 (4.00)20 (1.60) Anti-Parkinson drugs\*^,†,§^23 (1.26)54 (0.30)8 (1.04)17 (0.22)3 (2.40)4 (0.32) PPIs\*83 (4.56)657 (3.61)24 (3.12)243 (3.16)6 (4.80)68 (5.44)Type of MS was determined from original clinical records for 894 patients*MS* multiple sclerosis, *NSAIDs* non-steroidal anti-inflammatory drugs, *PPMS* primary progressive MS, *PPIs* proton pump inhibitors, *RRMS* relapsing-remitting MS\* *p* \< 0.05 for comparison between patients with MS and matched referent subjects (for all MS patients)^†^ *p* \< 0.05 for comparison between patients with RRMS and matched referent subjects^§^ *p* \< 0.05 for comparison between patients with PPMS and matched referent subjects^a^Includes 64 patients with secondary progressive MS

The online version of the original article can be found under doi:10.1007/s00415-014-7370-3.
